vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average – Time to Sell?

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $33.39 and traded as high as $33.53. vTv Therapeutics shares last traded at $32.35, with a volume of 136,838 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on VTVT. Wall Street Zen raised vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Zacks Research lowered vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. BTIG Research boosted their target price on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Rodman & Renshaw started coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

vTv Therapeutics Trading Down 1.0%

The business has a fifty day simple moving average of $33.39 and a two-hundred day simple moving average of $34.91. The stock has a market cap of $127.46 million, a PE ratio of -34.78 and a beta of 0.25.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $20.00 million. On average, research analysts predict that vTv Therapeutics Inc. will post -2.19 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

Hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics in the 4th quarter worth about $221,000. 683 Capital Management LLC bought a new position in shares of vTv Therapeutics in the 4th quarter worth about $731,000. Finally, Geode Capital Management LLC lifted its position in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.